止血产品市场规模、份额及成长分析（按产品、应用、最终用途及地区划分）－2026-2033年产业预测

预计到 2024 年，止血产品市场规模将达到 17.8 亿美元，到 2025 年将达到 18.8 亿美元，到 2033 年将达到 28.9 亿美元，在预测期（2026-2033 年）内，复合年增长率为 5.5%。

止血产品市场正经历强劲成长，这主要得益于医疗领域意识的提高和技术的进步。这些产品对于控製手术和创伤中的出血以及治疗各种出血性疾病至关重要。人口老化以及慢性病和外科手术的激增，推动了对这些解决方案的需求。此外，新兴市场医疗基础设施的改善也进一步促进了市场扩张。持续的研发投入正在推出更有效、更安全的止血产品。然而，监管障碍和高成本等挑战可能会限制市场成长。儘管存在这些障碍，但随着医疗标准和技术的不断发展，止血产品领域仍具备良好的发展前景。

止血产品市场驱动因素

止血产品市场受到更环保、更安全的止血产品以及旨在控制出血的创新药物和器械的持续研发的显着影响。这些技术进步不仅为外科手术中的出血管理提供了更有效的解决方案，还能改善病患的治疗效果。随着医疗机构越来越多地采用这些先进产品来提高医疗质量，对止血解决方案的需求持续增长，从而推动了该行业的成长。总而言之，这些产品的持续发展在塑造止血护理的未来方面发挥着至关重要的作用。

止血产品市场的限制因素

止血产品市场面临的主要挑战之一是其高成本。价格上涨会降低预算有限的医疗机构和某些地区患者获得这些产品的机会。这种经济障碍可能会阻碍先进止血解决方案的广泛应用，限制其市场份额，并可能影响病患照护品质。因此，成本仍然是一个突出的限制因素，影响着医疗机构对这些产品的投资意愿以及患者获得所需治疗的能力。

止血产品市场趋势

止血产品市场正呈现出一股显着的趋势，即微创技术优先考虑患者的安全和舒适度。包括医疗服务提供者和患者在内的相关人员越来越重视能够有效控制出血、同时最大限度地减少组织损伤和缩短恢復时间的解决方案。这种转变正在推动止血产品的创新，催生出能够改善手术效果并简化患者照护的新技术和方法。人们越来越倾向于选择恢復时间更短、住院时间更短的手术方式，这反映了医疗保健领域以价值为导向的整体趋势，即强调治疗方法的品质和效率。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球止血产品市场规模（依产品划分）及复合年增长率（2026-2033 年）

• 局部止血剂
  • 胶原蛋白
  • 氧化再生纤维素
  • 明胶
  • 多醣
• 输注型止血剂
  • 供体血液来源的血小板浓缩液
  • 血液来源的VIII因子
  • 新鲜冷冻血浆
  • 凝血酶原复合物
• 高级止血剂
  • 液体止血剂
  • 凝血酶
  • 纤维蛋白
  • 合成密封剂

全球止血产品市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 创伤
• 外科手术
• 血友病
• 心肌梗塞
• 中风
• 血栓症

全球止血产品市场规模（依最终用途划分）及复合年增长率（2026-2033 年）

• 医院
• 门诊手术中心
• 其他的

全球止血产品市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• CSL Behring（Australia）
• Haemonetics Corporation（USA）
• Octapharma AG（Switzerland）
• Baxter International Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Becton, Dickinson and Company（USA）
• Medtronic plc（Ireland）
• Siemens Healthineers AG（Germany）
• Abbott Laboratories（USA）
• Roche Holding AG（Switzerland）
• Thermo Fisher Scientific Inc.（USA）
• Grifols, SA（Spain）
• Instrumentation Laboratory（Werfen）（USA）
• Stago Group（France）
• Sysmex Corporation（Japan）
• Siemens Healthineers AG（Germany）
• Danaher Corporation（USA）
• LivaNova PLC（UK）
• CryoLife, Inc.（USA）

结论与建议

Hemostasis Products Market size was valued at USD 1.78 Billion in 2024 and is poised to grow from USD 1.88 Billion in 2025 to USD 2.89 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The hemostasis products market is experiencing robust growth driven by heightened awareness and technological advancements in the medical field. These products are essential for managing bleeding during surgeries and trauma events, as well as treating various bleeding disorders. The increasing aging population, alongside a surge in chronic illnesses and surgical procedures, fuels demand for these solutions. Additionally, improved healthcare infrastructure in emerging markets further supports market expansion. Continuous research and innovation are introducing more effective and safer hemostasis products. However, challenges such as regulatory hurdles and high costs may limit market growth. Despite these obstacles, the hemostasis products sector is well-positioned for ongoing development as healthcare standards and technologies evolve.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemostasis Products market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemostasis Products Market Segments Analysis

Global Hemostasis Products Market is segmented by Products, Application, End Use and region. Based on Products, the market is segmented into Topical Hemostasis, Infusible Hemostasis and Advanced Hemostasis. Based on Application, the market is segmented into Trauma, Surgery, Hemophilia, Myocardial Infarction, Stroke and Thrombosis. Based on End Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemostasis Products Market

The Hemostasis Products market is significantly influenced by advancements in the development of greener and safer hemostatic products, as well as innovative agents and devices designed to control bleeding. These technological enhancements not only provide more effective solutions for managing bleeding during surgical procedures but also lead to better patient outcomes. As healthcare providers increasingly adopt these advanced products to elevate the quality of care, the demand for hemostasis solutions continues to rise, driving growth within this sector. Overall, the continuous evolution of these products plays a crucial role in shaping the future of hemostasis treatments.

Restraints in the Hemostasis Products Market

A significant challenge facing the hemostasis products market is the high cost of these items. The elevated prices can make them less attainable for healthcare facilities operating with limited budgets, as well as for patients in certain areas. This financial barrier can impede the widespread adoption of advanced hemostasis solutions, thereby restricting their presence in the market and potentially impacting the quality of patient care. As a result, the cost factor remains a prominent limitation, influencing both healthcare providers' willingness to invest in these products and patients' ability to access necessary treatments.

Market Trends of the Hemostasis Products Market

The Hemostasis Products market is witnessing a significant trend towards minimally invasive techniques that prioritize patient safety and comfort. Stakeholders in healthcare, including providers and patients, are increasingly favoring solutions that effectively manage bleeding while minimizing tissue damage and recovery time. This shift is driving innovation in hemostasis products, as new technologies and practices emerge to enhance surgical outcomes and streamline patient care. The rising preference for procedures that allow for quicker recovery and shorter hospital stays reflects the overarching trend in healthcare towards value-based care, emphasizing quality and efficiency in treatment methodologies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemostasis Products Market Size by Products & CAGR (2026-2033)

• Market Overview
• Topical Hemostasis
  • Collagen
  • Oxidized Regenerated Cellulose
  • Gelatin
  • Polysaccharide
• Infusible Hemostasis
  • Platelet Concentrates from Donor Blood
  • FVIII Derived from Blood
  • Fresh Frozen Plasma
  • Prothrombin Complex
• Advanced Hemostasis
  • Flowable
  • Thrombin
  • Fibrin
  • Synthetic Sealants

Global Hemostasis Products Market Size by Application & CAGR (2026-2033)

• Market Overview
• Trauma
• Surgery
• Hemophilia
• Myocardial Infarction
• Stroke
• Thrombosis

Global Hemostasis Products Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Others

Global Hemostasis Products Market Size & CAGR (2026-2033)

• North America (Products, Application, End Use)
  • US
  • Canada
• Europe (Products, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Products, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Products, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Products, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instrumentation Laboratory (Werfen) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stago Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CryoLife, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations